Venlafaxine or Estradiol for Hot Flashes: Four Checks

When choosing treatment for hot flashes, ask the clinician to separate symptom relief from the risks that matter in your history. Bring your symptom record, medicine list and questions about blood pressure, bleeding and previous treatment. These four checks put one comparison trial in context.

Who was studied?

MsFLASH randomized 339 healthy women aged 40–62 for eight weeks: oral estradiol 0.5 mg, extended-release venlafaxine 75 mg or placebo. Breast cancer and uncontrolled hypertension were excluded; 330 provided diaries at four or eight weeks.¹

How much beyond placebo?

At week eight, estradiol reduced episodes by 2.3 more daily than placebo (95% CI 1.3–3.4); venlafaxine by 1.8 (0.8–2.7). These are placebo-adjusted differences, not percentage reductions.¹

Were they equivalent?

The active comparison was post hoc: 0.6 episodes/day favored estradiol, with the 95% CI ranging from 1.8 daily favoring estradiol to 0.6 favoring venlafaxine. The trial was not powered to establish noninferiority. Eight weeks cannot establish long-term safety. NIH funded it.¹

Which risks matter?

US Effexor XR use for hot flashes is off-label. Its label requires controlling high blood pressure before treatment and monitoring during it. Review other medicines, especially contraindicated MAO inhibitors and serotonergic combinations. Discuss bleeding risk with aspirin, anti-inflammatory medicines or anticoagulants. Agree a gradual stopping plan rather than stopping suddenly.²

Its boxed warning concerns increased suicidal thoughts and behavior in pediatric and young adult patients; monitoring applies to all antidepressant users. Contact the prescriber promptly about suicidal thoughts or concerning mood changes. Discuss driving impairment before relying on your usual alertness.²

The US oral estradiol label includes menopausal vasomotor symptoms. For someone with a uterus, it calls for a progestin to reduce endometrial-cancer risk. Review unexplained bleeding, breast-cancer history, clots, stroke and liver disease before treatment. Report unexpected vaginal bleeding for assessment. This short trial is not a plan for continuing estrogen without endometrial protection.³

UK NICE⁴ guidance does not routinely offer SSRIs or SNRIs as first-line treatment for hot flashes alone. That recommendation concerns placement in care, not a claim that venlafaxine cannot reduce symptoms. Ask why a proposed option fits your history, preferences and previous treatment.⁴

My Body Changed. Now What? includes “Is It Right for You?” and its Visit Brief questions about age and stage, uterus status, clot or breast-cancer history, route and nonhormonal alternatives. Bring those questions to the appointment and agree when symptom relief and side effects will be reviewed separately.